Neutralization of complement regulatory proteins CD55 and CD59 augments therapeutic effect of herceptin against lung carcinoma cells.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Oncology Report

• Publication date

  2009-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3892/OR_00000368PMID 19424617
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mapping of binding epitopes of a human decay-accelerating factor monoclonal antibody capable of enhancing rituximab-mediated complement-dependent cytotoxicity.

  2008cited by this paper
• In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab.

  2007cited by this paper
• Minimal Residual Disease in Ovarian Cancer as a Target for Complement‐Mediated mAb Immunotherapy

  2006cited by this paper
• Herceptin: mechanisms of action and resistance.

  2006cited by this paper
• Her2-Targeted Therapies in Non–Small Cell Lung Cancer

  2006cited by this paper
• Monoclonal antibody therapy of leukaemias and lymphomas

  2005cited by this paper
• Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin.

  2005cited by this paper
• Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.

  2005cited by this paper
• Do poor-prognosis breast tumours express membrane cofactor proteins (CD46)?

  2005cited by this paper
• Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement‐regulatory proteins CD55 and CD59

  2005cited by this paper
• Functional idiotopes: tumor antigen-directed expression of CD8+ T-cell epitopes nested in unique NH2-terminal VH sequence of antiidiotypic antibodies?

  2005cited by this paper
• Terminal Complement Complex: Regulation of Formation and Pathophysiological Functions

  2004cited by this paper
• Tumor-Specific Inhibition of Membrane-Bound Complement Regulatory Protein Crry with Bispecific Monoclonal Antibodies Prevents Tumor Outgrowth in a Rat Colorectal Cancer Lung Metastases Model

  2004cited by this paper
• A Comparison of the in Vitro and in Vivo Activities of IgG and F(ab′)2 Fragments of a Mixture of Three Monoclonal Anti-Her-2 Antibodies

  2004cited by this paper
• Beta‐glucan enhanced killing of renal cell carcinoma micrometastases by monoclonal antibody G250 directed complement activation

  2004cited by this paper
• Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease.

  2004cited by this paper
• Complement regulatory proteins in normal human esophagus and esophageal squamous cell carcinoma

  2004cited by this paper
• Capsaicinoids cause inflammation and epithelial cell death through activation of vanilloid receptors.

  2003cited by this paper
• HER2/neu expression in malignant lung tumors.

  2002cited by this paper
• The Inhibitory Effect of CD46, CD55, and CD59 on Complement Activation After Immunotherapeutic Treatment of Cervical Carcinoma Cells with Monoclonal Antibodies or Bispecific Monoclonal Antibodies

  2002cited by this paper
• Mechanism of action of rituximab

  2002cited by this paper
• Non-small cell lung cancer clinical trials with trastuzumab: their foundation and preliminary results.

  2002cited by this paper
• Tumor Cell Expression of CD59 Is Associated With Resistance to CD20 Serotherapy in Patients With B-Cell Malignancies

  2001cited by this paper
• Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents.

  2001cited by this paper
• The endothelium is an extrahepatic site of synthesis of the seventh component of the complement system

  2000cited by this paper
• Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.

  1996cited by this paper
• Inhibition of human lung cancer cell line growth by an anti-p185HER2 antibody.

  1993cited by this paper
• Synthesis of C3, C5, C6, C7, C8, and C9 by Human Fibroblasts

  1990cited by this paper

• Pro‐ and Anti‐Inflammatory Role of Complement in Cancer

  2025cites this paper
• Complement regulators as novel targets for anti-cancer therapy: A comprehensive review.

  2025cites this paper
• Complement system in tumor growth and metastases

  2025cites this paper
• The complement system in clinical oncology: Applications, limitations and challenges.

  2024cites this paper
• CD59 Protects Primary Human Cerebrovascular Smooth Muscle Cells from Cytolytic Membrane Attack Complex

  2024cites this paper
• CD59 Protects Primary Human Cerebrovascular Smooth Muscle Cells from Cytolytic Membrane Attack Complex

  2024cites this paper
• The tumor immune microenvironment and T-cell-related immunotherapies in colorectal cancer

  2024cites this paper
• Human papillomavirus-mediated expression of complement regulatory proteins in human cervical cancer cells.

  2023cites this paper
• Functionalized Graphene Quantum Dots (GQDs) based Label-Free Optical Fluorescence Sensor for CD59 Antigen Detection and Cellular Bioimaging

  2023cites this paper
• Deciphering the Role of the Anaphylatoxin C3a: A Key Function in Modulating the Tumor Microenvironment

  2023influential citation
• mRNA–miRNA bipartite networks reconstruction in different tissues of bladder cancer based on gene co-expression network analysis

  2022cites this paper
• Bispecific mAb2 Antibodies Targeting CD59 Enhance the Complement-Dependent Cytotoxicity Mediated by Rituximab

  2022cites this paper
• Inside-Out of Complement in Cancer

  2022cites this paper
• Complement System: An Immunotherapy Target in Colorectal Cancer

  2022cites this paper
• Complement in Tumourigenesis and the Response to Cancer Therapy

  2021cites this paper
• Low level of complement factor H increases the risk of cancer-related death in patients with small-cell lung cancer

  2021cites this paper
• Buffy Coat Immunotranscriptomics for Diagnosis of Malignant Pleural Mesothelioma

  2021cites this paper
• LncRNA MAFG-AS1 promotes the malignant phenotype of ovarian cancer by upregulating NFKB1-dependent IGF1

  2021cites this paper
• Viral Evasion of the Complement System and Its Importance for Vaccines and Therapeutics

  2020cites this paper
• Dichotomy of Complement System: Tumorigenesis or Destruction.

  2020cites this paper
• Tumor-Sensitive Biodegradable Nanoparticles of Molecularly Imprinted Polymers-Stabilized Fluorescent Zeolitic Imidazolate Framework-8 for Targeted Imaging and Drug Delivery.

  2020cites this paper
• Deciphering the Intricate Roles of Radiation Therapy and Complement Activation in Cancer.

  2020cites this paper
• Impact of Losing hRpn13 Pru or UCHL5 on Proteasome Clearance of Ubiquitinated Proteins and RA190 Cytotoxicity

  2020cites this paper
• Therapeutic Lessons to be Learned From the Role of Complement Regulators as Double-Edged Sword in Health and Disease

  2020cites this paper
• The Role of Complement in the Mechanism of Action of Therapeutic Anti-Cancer mAbs

  2020cites this paper
• Unveiling the immunomodulatory properties of Haemonchus contortus adhesion regulating molecule 1 interacting with goat T cells

  2020cites this paper
• Epitope Molecularly Imprinted Polymer Nanoparticles for Chemo-/Photodynamic Synergistic Cancer Therapy Guided by Targeted Fluorescence Imaging.

  2020cites this paper
• The Role of Membrane Bound Complement Regulatory Proteins in Tumor Development and Cancer Immunotherapy

  2019cites this paper
• A novel therapeutic anti‑CD55 monoclonal antibody inhibits the proliferation and metastasis of colorectal cancer cells.

  2019cites this paper
• Proteomic analysis identifies mechanism(s) of overcoming bortezomib resistance via targeting ubiquitin receptor Rpn13

  2019cites this paper
• Regional Gene Therapy for Cancer

  2019cites this paper
• Development and preclinical validation of a novel covalent ubiquitin receptor Rpn13 degrader in multiple myeloma

  2019cites this paper
• Targeting the Complement Pathway as a Therapeutic Strategy in Lung Cancer

  2019cites this paper
• Generation of erythroid cells from polyploid giant cancer cells: re-thinking about tumor blood supply

  2018cites this paper
• Complement as a Biological Tool to Control Tumor Growth

  2018cites this paper
• CD59: a promising target for tumor immunotherapy.

  2018cites this paper
• Complement system's role in cancer and its therapeutic potential in ovarian cancer

  2018cites this paper
• Proteasome dysregulation in human cancer: implications for clinical therapies

  2017cites this paper
• The role of the complement system in cancer

  2017cites this paper
• Structure of the Rpn13-Rpn2 complex provides insights for Rpn13 and Uch37 as anticancer targets

  2017cites this paper
• Characterisation of glioblastoma subtypes: implications for therapy resistance

  2016cites this paper
• Cytotoxic mechanisms of immunotherapy: Harnessing complement in the action of anti-tumor monoclonal antibodies.

  2016cites this paper
• Targeting proteasome ubiquitin receptor Rpn13 in multiple myeloma

  2016cites this paper
• CD147 and matrix-metalloproteinase-2 expression in metastatic and non-metastatic uveal melanomas

  2016cites this paper
• Macrophages form functional vascular mimicry channels in vivo

  2016cites this paper
• The dual role of complement in cancer and its implication in anti-tumor therapy.

  2016cites this paper
• Intravitreally Injected HCmel12 Melanoma Cells Serve as a Mouse Model of Tumor Biology of Intraocular Melanoma

  2016cites this paper
• Targeted delivery of siRNA using transferrin-coupled lipoplexes specifically sensitizes CD71 high expressing malignant cells to antibody-mediated complement attack

  2015cites this paper
• A systems biology approach for the identification of significantly perturbed genes

  2015cites this paper
• Regulation of Complement Dependent Cytotoxicity by TGF-β-induced Epithelial-Mesenchymal Transition

  2015cites this paper
• Membrane-bound complement regulatory proteins are prognostic factors of operable breast cancer treated with adjuvant trastuzumab: a retrospective study.

  2014influential citation
• GRP78 promotes the invasion of pancreatic cancer cells by FAK and JNK

  2014cites this paper
• Rapid Degradation of the Complement Regulator, CD59, by a Novel Inhibitor*

  2014cites this paper
• A novel bullet hits the proteasome.

  2013cites this paper
• Immunologic Aspects of Prostate Cancer

  2013cites this paper
• Experimental hypoxia does not influence gene expression and protein synthesis of Eph receptors and ephrin ligands in human melanoma cells in vitro

  2013cites this paper
• Investigating the tumour promoting roles of complement membrane attack complex using global gene expression analysis.

  2013cites this paper
• Generation of 1E8 Single Chain Fv-Fc Construct Against Human CD59

  2012cites this paper
• Increased expression of CD55 correlates with tumor progression and poor prognosis in nasopharyngeal carcinoma.

  2012cites this paper
• Embryonic Stem Cell Markers

  2012cites this paper
• Immunohistochemical Expression and Prognostic Value of CD97 and Its Ligand CD55 in Primary Gallbladder Carcinoma

  2012cites this paper
• Pre‐Sorting Endosomal Transport of the GPI‐Anchored Protein, CD59, is Regulated by EHD1

  2011cites this paper
• Inflammatory Macrophages Induce Nrf2 Transcription Factor-dependent Proteasome Activity in Colonic NCM460 Cells and Thereby Confer Anti-apoptotic Protection*

  2011cites this paper
• Application of a novel inhibitor of human CD59 for the enhancement of complement-dependent cytolysis on cancer cells

  2011cites this paper
• Immunogenicity of biotherapeutics: a need for consensus on flexibility of approach.

  2010cites this paper
• Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape.

  2010cites this paper
• Dual role of complement in tumour growth and metastasis (Review).

  2010cites this paper
• Salivary analysis of oral cancer biomarkers

  2009cites this paper
• Increased proteasome subunit protein expression and proteasome activity in colon cancer relate to an enhanced activation of nuclear factor E2-related factor 2 (Nrf2)

  2009cites this paper